Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Natera, Inc. (NTRA) Discusses Findings from ESMO Congress Transcript
03:57pm, Thursday, 23'rd Oct 2025
Natera, Inc. (NASDAQ:NTRA ) Discusses Findings from ESMO Congress October 23, 2025 8:00 AM EDT Company Participants Mike Brophy - Chief Financial Officer Alexey Aleshin - GM of Oncology and ECD & Chie
2,005 Shares in Natera, Inc. $NTRA Bought by Sequoia Financial Advisors LLC
03:43am, Wednesday, 22'nd Oct 2025
Sequoia Financial Advisors LLC purchased a new stake in shares of Natera, Inc. (NASDAQ: NTRA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
01:05am, Monday, 20'th Oct 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 IMvigor011 clin
Natera Named to Fast Company's Next Big Things in Tech List
08:00am, Thursday, 16'th Oct 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named to Fast Company's 2025 Next Big Things in T
Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
08:00am, Monday, 13'th Oct 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will host a conference call and webcast on Thursday, Oct.
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
06:10pm, Sunday, 12'th Oct 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 14 studies featuring its technology will be presented at the
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Monday, 06'th Oct 2025
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Enrollment Tops 1,600 in Natera's EXPAND Trial of Single Gene NIPT
08:00am, Wednesday, 01'st Oct 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a milestone in the EXPAND trial with the enrollmen
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
08:00am, Tuesday, 30'th Sep 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a peer-reviewed manuscript in the Journal of Cl
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
08:00am, Monday, 29'th Sep 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology
Natera, Inc. (NTRA) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
10:53am, Wednesday, 24'th Sep 2025
Natera, Inc. (NASDAQ:NTRA ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 10:30 AM EDT Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Ev
Can Natera Stock Reach $500?
10:10am, Monday, 15'th Sep 2025
Let's start with something remarkable. Natera (NASDAQ: NTRA) just marked its 10th anniversary as a public company, and what a journey it has been.
Natera, Inc. (NTRA) Presents At Baird Global Healthcare Conference 2025 Transcript
12:31pm, Wednesday, 10'th Sep 2025
Natera, Inc. (NASDAQ:NTRA ) Baird Global Healthcare Conference 2025 September 9, 2025 8:30 AM EDT Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Conference C
Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability
02:40pm, Tuesday, 02'nd Sep 2025
For my first rating of Natera, I called it a buy, while today's consensus seems to be between a hold and a strong buy. Both proven revenue growth and expected future growth outlooks are upside drivers
Natera Provides Update on Patent Litigation with NeoGenomics
08:18am, Friday, 29'th Aug 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its intellectual property litigation with NeoGe
